Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic dysfunction-associated steatohepatitis to a market that could reach $16 billion by ...
Discover how Akero Therapeutics' EFX outshines competitors in MASH treatment, with groundbreaking results and strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback